---
schema_version: "secwatch.filing_event.v1"
accession: "0001156039-24-000093"
form_type: "8-K"
ticker: "ELV"
cik: "0001156039"
company_name: "Elevance Health, Inc."
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:47:14.539571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Elevance Health reaffirms FY2024 net income >$34.05, adjusted >$37.20 per share

## Summary
- Net income guidance for FY2024 greater than $34.05 per diluted share including approximately $3.15 per share of net unfavorable items.
- Adjusted net income guidance greater than $37.20 per diluted share, excluding the unfavorable items.
- Guidance does not include any adjustment items beyond those reported in Q1 2024 earnings release.
- Company officers reaffirming guidance during investor meetings over the next several weeks.

## SEC filing metadata
- accession: 0001156039-24-000093
- form_type: 8-K
- ticker: ELV
- cik: 0001156039
- company_name: Elevance Health, Inc.
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1156039/000115603924000093/0001156039-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1156039/000115603924000093/item701guidancejune2024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001156039-24-000093
- JSON: https://secwatch.observer/filing/0001156039-24-000093.json
- Plain text: https://secwatch.observer/filing/0001156039-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.